In my recent post, Betting on the Founder: Why Talent is our Greatest Tech Transfer Asset, I explored why investing in people is the most effective way to transition academic innovations out of the lab. While the human element is the philosophical foundation of that argument, there is an equally compelling financial and structural case to be made.

Basic science is the lifeblood of a research university. It expands our understanding of the world and seeds future breakthroughs. However, that basic science achieves its ultimate purpose when it improves lives, creates jobs, and generates wealth for both the founders and the institution.

Historically, a dominant path for this translation was traditional direct licensing to large corporations. That pathway still exists today, and many companies continue to license early‑stage university patents. Yet recent data suggest a significant evolution in how the broader market, including venture capitalists and acquiring corporations, value early‑stage research: increasingly, university spinouts are emerging as the central vehicle for commercialization.

The National Data: A Shift in Value Creation

Consider these key metrics from the most recent AUTM report:

• A Decline in Traditional Royalties: Income from running royalties dropped by more than 40%, and gross licensing income declined by 24%.
• A Rise in Equity Returns: In the exact same period, revenue generated from equity "cash-outs" (exits) increased by 25%.
• A Strong Research Pipeline: Total research expenditures topped $109 billion, and new invention disclosures increased across the board.

This shift comes down to risk mitigation. By the time a larger company comes in to acquire the startup or partner with it, the core technology has been significantly de-risked. The spinout serves as the essential bridge that translates raw basic science into a validated commercial asset, and the AUTM data reflects a market that is increasingly willing to pay for that progress rather than taking on the early technical risk internally.

What this data tells us is not that patents have lost their value. Rather, it shows that the broader market places a growing premium on the tangible progress a startup achieves by advancing the technology, engaging early customers, and navigating the earliest regulatory hurdles.

The Federal Endorsement: A $6 Million De-Risking Pipeline

If there is any doubt that the market has shifted toward this founder centric model, we need only look at how the federal government is allocating its research dollars. The NSF and other federal agencies explicitly recognize that basic research requires a dedicated, well funded vehicle to survive the gap between the lab and the commercial market.

As I recently detailed in my blog posts about the NSF I-Corps and Translation to Practice (TTP) programs, federal agencies are providing massive capital injections to support teams as they de-risk their technology.

The metrics and funding scale speak for themselves:

• NSF I-Corps Success: Since its launch in 2012, over 3,000 academic teams have completed the I-Corps program. Over half of those teams went on to form startups, which have collectively raised $7 billion in private capital and over $1.7 billion in public funding.
• The TTP Runway: The new TTP program provides tiered, non-dilutive funding tracks to advance technology readiness, allowing teams to access up to $3.8 million across three distinct phases.
• Stacking the Capital: When researchers combine I-Corps training, the stacked TTP tracks, and subsequent SBIR/STTR Phase I and II awards, a single academic innovation can receive over $6 million in aggregate, over multiple funding stages in federal, non-dilutive support.

This infrastructure exists for one clear reason. The federal government understands that a startup, driven by a trained founding team, is often the most efficient vehicle for advancing early‑stage technologies and validating specific business needs.

The Venture Capital Multiplier

This $6 million federal pipeline serves one primary function: it prepares startups for venture capital.

Venture capitalists typically do not license patents or IP directly. They invest in teams capable of executing scalable business models. Historically, VCs have been highly averse to foundational scientific risk. However, because federal funding absorbs this early technical risk, academic startups become exceptionally attractive targets for private investors. VCs can then focus their capital primarily on market execution and scaling/growth.

The market clearly rewards this approach. National Academies' research shows that SBIR and STTR recipients are far more successful at attracting follow on venture capital than their peers who lack that federal validation. Likewise, PitchBook's tracking of the billions flowing into university spinouts every year suggests that private investors are looking for the structural de-risking that only a dedicated founding team can provide.

Aligning the NYU Ecosystem with Global Market Trends

Recognizing that startups are a primary driver of commercialization success, we are focused on intentionally aligning our institutional strategy with these market shifts. At NYU, we have an opportunity to further optimize our environment to ensure that groundbreaking research has a clear, supported pathway from the lab to the world.

To catalyze this movement, we are focusing our efforts in two key areas:

1. Expanding Investment in Commercialization: Through the NYU Leslie Entrepreneurial Institute and our associated programs, we provide the non-dilutive capital, expert mentorship, and structured support necessary to navigate the high-risk transition from discovery to startup. Resourcing these areas ensures that NYU's research is not just patented, but is actively developed into a market-ready asset.
2. Building a More Founder-Friendly Environment: To compete in today's fast-moving economy, we are working toward lowering the barriers to entry for our faculty and student innovators. By continually looking for ways to reduce administrative friction and offering increasingly standardized, transparent terms for spinouts, we aim to make it easier for our researchers to take the entrepreneurial leap and maintain the momentum required for commercial success.

The Path Forward

We do not need to rely on isolated outliers to see success in this space. Across the country, faculty members and graduate students are successfully launching companies that deliver profound societal and economic impact on a daily basis.

Universities produce some of the most innovative basic science in the world. By leaning into the data, investing in our commercialization infrastructure, and supporting the founders who drive these startups, we can ensure that our research achieves its maximum possible impact. None of this means abandoning traditional licensing. It means aligning our incentives, infrastructure, and support so that when spinouts are the right path, our researchers are empowered to take it.

How to Get Started at NYU

If you are a faculty member, postdoc, or graduate researcher looking to explore the commercial potential of your work, you do not have to navigate this landscape alone.

The NYU Leslie Entrepreneurial Institute provides the training, mentorship, and connection to federal funding pipelines like I-Corps and TTP that are necessary to de-risk your technology. Whether you are just beginning to think about a use case or are ready to pursue non-dilutive federal grants, our team is here to help you bridge the gap between the lab and the world.

I encourage you to reach out for a coaching session with a member of our team or explore our upcoming Tech Venture Workshops to see how we can support your journey.